Contrasting Prestige Consumer Healthcare (NYSE:PBH) and INLIF (NASDAQ:INLF)

Prestige Consumer Healthcare (NYSE:PBH) and INLIF (NASDAQ:INLF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Prestige Consumer Healthcare and INLIF’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	17.48%	11.54%	6.16%
INLIF	N/A	N/A	N/A

Insider and Institutional Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prestige Consumer Healthcare and INLIF, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1	3	2	0	2.17
INLIF	1	0	0	0	1.00

Prestige Consumer Healthcare presently has a consensus price target of $70.75, suggesting a potential upside of 55.64%. Given Prestige Consumer Healthcare’s stronger consensus rating and higher probable upside, equities analysts plainly believe Prestige Consumer Healthcare is more favorable than INLIF.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and INLIF”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09 billion	1.98	$190.30 million	$3.91	11.63
INLIF	$18.41 million	2.89	-$5.45 million	N/A	N/A

Prestige Consumer Healthcare has higher revenue and earnings than INLIF.

Volatility and Risk

Prestige Consumer Healthcare has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, INLIF has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats INLIF on 10 of the 12 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About INLIF

INLIF Ltd. is a holding company, which engages in the development of injection molding machine-dedicated manipulator arms. Its products include: Three-axis robot, Five-axis robot and bull head type manipulator. The company was founded on January 4, 2023 and is headquartered in Quanzhou, China.